

# Axel Dignass

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7048491/publications.pdf>

Version: 2024-02-01

40  
papers

5,040  
citations

361296

20  
h-index

302012

39  
g-index

45  
all docs

45  
docs citations

45  
times ranked

5517  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 28-62.  | 0.6 | 1,247     |
| 2  | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 991-1030.   | 0.6 | 1,106     |
| 3  | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 965-990.   | 0.6 | 715       |
| 4  | European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.   | 0.6 | 425       |
| 5  | Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.   | 0.6 | 331       |
| 6  | An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 347-357.  | 1.9 | 157       |
| 7  | Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. <i>International Journal of Chronic Diseases</i> , 2018, 2018, 1-11.  | 1.9 | 134       |
| 8  | Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 762-769.   | 2.4 | 130       |
| 9  | Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1303-1318. | 1.9 | 87        |
| 10 | The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.   | 4.9 | 58        |
| 11 | Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 991-1008.  | 1.9 | 48        |
| 12 | Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1032-1043.e1.   | 0.6 | 48        |
| 13 | Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 970-980.   | 0.6 | 37        |
| 14 | Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 812-820.      | 0.6 | 35        |
| 15 | Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1286-1295.  | 1.9 | 31        |
| 16 | A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 670-676.   | 0.6 | 28        |
| 17 | Review article: treating a target for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 610-617.   | 1.9 | 28        |
| 18 | Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1721-1737.  | 0.9 | 25        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 597-606.   | 0.7 | 22        |
| 20 | Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease. United European Gastroenterology Journal, 2020, 8, 804-813.   | 1.6 | 17        |
| 21 | Management of Inflammatory Bowel Diseases during Pregnancy. Digestive Diseases, 2009, 27, 341-346.   | 0.8 | 16        |
| 22 | Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scandinavian Journal of Gastroenterology, 2018, 53, 1059-1065.   | 0.6 | 16        |
| 23 | Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 316-322.   | 0.6 | 13        |
| 24 | Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scandinavian Journal of Gastroenterology, 2018, 53, 442-448.  | 0.6 | 12        |
| 25 | Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. Journal of Medical Economics, 2020, 23, 415-427.   | 1.0 | 11        |
| 26 | A multicentre prospective cohort study assessing the effectiveness of budesonide MMX <sup>®</sup> (Cortiment <sup>®</sup> MMX <sup>®</sup> ) for active, mild-to-moderate ulcerative colitis. United European Gastroenterology Journal, 2019, 7, 1171-1182.                                      | 1.6 | 9         |
| 27 | Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. Journal of Medical Economics, 2021, 24, 279-290.   | 1.0 | 7         |
| 28 | Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 2021, , 1-8.  | 0.6 | 6         |
| 29 | Interferon- $\gamma$ modulates intestinal epithelial cell function in-vitro through a TGF $\beta$ -dependent mechanism. Regulatory Peptides, 2011, 168, 27-31.   | 1.9 | 5         |
| 30 | Complementary Therapies in Inflammatory Bowel Diseases. Current Drug Targets, 2014, 15, 1079-1088.   | 1.0 | 5         |
| 31 | Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies – authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 705-706.   | 1.9 | 4         |
| 32 | Overcoming the barriers to dissemination and implementation of quality measures for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology (UEG) position statement. United European Gastroenterology Journal, 2021, 9, 120-126. | 1.6 | 4         |
| 33 | Editorial: which iron preparation for patients with IBD? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 195-196.  | 1.9 | 3         |
| 34 | Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. Scandinavian Journal of Gastroenterology, 2019, 54, 178-187.  | 0.6 | 3         |
| 35 | Letter: inflammatory bowel disease guidelines and conflicts of interest. Alimentary Pharmacology and Therapeutics, 2013, 38, 445-445.  | 1.9 | 0         |
| 36 | Editorial: the management of IBD during pregnancy and lactation - author's reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 1248-1248.   | 1.9 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Letter: leucocytapheresis as a nonpharmacologic treatment for patients with ulcerative colitis during pregnancy – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 235-236.   | 1.9 | 0         |
| 38 | Letter: inconsistency in reporting of hypophosphataemia after intravenous iron – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 643-644.  | 1.9 | 0         |
| 39 | Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. <i>Advances in Therapy</i> , 2019, 36, 1817-1820.   | 1.3 | 0         |
| 40 | Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2021, , 1-2. | 1.0 | 0         |